Absci and AstraZeneca Partner to Leverage AI in Cancer Treatment Discovery
A frontrunner in generative AI antibody discovery, Absci, has partnered with biopharmaceutical giant AstraZeneca to capitalize on Artificial Intelligence (AI) in the quest for a novel cancer treatment. The collaboration aims to expedite the discovery of a potentially game-changing cancer therapy by integrating Absci’s generative AI platform with AstraZeneca’s expertise in oncology.
Generative AI Technology to Craft Therapeutic Candidate Antibodies
Under the agreement, Absci will deploy its pioneering generative AI technology to create a therapeutic candidate antibody tailored for a specific oncology target. The collaboration encompasses an upfront commitment, substantial R&D funding, milestone payments, and royalties on future product sales.
Absci’s Integrated Drug Creation Platform
Absci’s Integrated Drug Creation platform combines generative AI and scalable wet-lab technologies. By scrutinizing millions of protein-protein interactions, the platform generates proprietary data that fuels Absci’s proprietary AI models, facilitating the design of antibodies that are later validated through wet-lab experiments.
Accelerated Drug Discovery Outcomes
The entire drug discovery cycle can be completed within approximately six weeks, enhancing the probability of successful development outcomes for biologic drug candidates. This collaboration between Absci and AstraZeneca demonstrates how AI can be used to revolutionize drug discovery.
Puja Sapra, SVP of Biologics Engineering & Oncology Targeted Delivery at AstraZeneca
Puja Sapra, PhD, SVP of Biologics Engineering & Oncology Targeted Delivery at AstraZeneca, commented on the collaboration: “This exciting opportunity to utilize Absci’s de novo AI antibody creation platform to design a potential new antibody therapy in oncology.”
Absci’s De Novo Antibody Creation Platform
Absci’s state-of-the-art ‘zero-shot’ generative AI model has been designed and validated to create de novo antibodies, which could revolutionize drug discovery in the field of oncology.
Absci and AstraZeneca Collaboration Benefits Drug Discovery
The collaboration between Absci and AstraZeneca showcases how AI can be used to accelerate drug discovery, potentially improving the lives of cancer patients by designing therapeutic candidate antibodies with the potential to make a significant impact in the field of oncology.
